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Dysregulation of any of the factors
involved in the inflammatory response
is important in the development of
disease, and failure to resolve this
response leads to chronic inflammation.
Psoriasis is a common immune-media-
ted chronic inflammatory skin disease
characterized by epidermal hyperplasia,
parakeratosis, dermal inflammatory cell
infiltration, and angiogenesis (Nestle
et al., 2009). There is increased growth
and altered differentiation of keratino-
cytes in both the epidermal granular and
cornified layers in psoriasis (Perera
et al., 2012).
Angiogenesis has a key role in the
pathogenesis of psoriasis, but as yet
research into antiangiogenic therapies
for this chronic inflammatory condition
has been limited (Schonthaler et al.,
2009). Vascular endothelial growth
factor (VEGF), the most potent angio-
genic factor, and its receptors, VEGFR-1
and VEGFR-2, are overexpressed by
psoriatic papillary dermal microvas-
cular endothelial cells (Detmar et al.,
1994). Transgenic delivery of VEGF to
mouse skin leads to an inflammatory
condition resembling human psoriasis
(Xia et al., 2003). We further define
the overexpression of VEGFRs, includ-
ing VEGFR-1, VEGFR-2, and VEGFR-3,
in lesional psoriatic epidermal keratino-
cytes (Man et al., 2008). The anti-
VEGFR-2 antibody reduced the vessels
in SCID-psoriasis xenograft and the
PASI and thickness of epidermis in
imiquimod-induced Balb/c psoriasiform
skin (Figure 1). Both calcium and VEGF
regulate VEGFR expression in psoriatic
epidermis. More importantly, calcium is
a potential regulator for VEGFR inde-
pendent of VEGF (Man et al., 2008). In
addition, systemic anti-VEGF treatment
strongly reduces skin inflammation in a
mouse model of psoriasis (Schonthaler
et al., 2009). Valpha, a protein targeting
VEGF-A and TNF-a showing double
anti-angiogenic and anti-inflammatory
effect, alleviates inflammation in a
mouse model of psoriasis by norma-
lizing the hyperplastic epidermis and
vascular abnormalities (Jung et al.,
2011).
Pituitary tumor transforming gene 1
(PTTG1) could promote tumor angio-
genesis. PTTG1 expression is enhanced
in the psoriatic epidermis and induces
TNF-a production from keratinocytes
(Ishitsuka et al., 2013). Our data have
shown that PTTG1 in psoriatic epi-
dermis is about 5-fold of normal ones.
Different cell cycle of psoriatic kera-
tinocytes expresses different amount
of PTTG1 correlates with Cyclin B1
(Cai et al., 2014). Further investiga-
tion should be done to clarify the
role of PTTG1 in the pathogenesis of
psoriasis.
Disrupted balance of angiogenic and
antiangiogenic signals contributes to the
proliferation of psoriatic keratinocytes.
VEGF antagonist, PEDF (Pigment epithe-
lium-derived factor), has an inhibitory
role in proliferation and migration of
keratinocytes. Topical application of
anti-angiogenic peptides based on pig-
ment epithelium-derived factor reduced
epidermal thickness and angiogenesis
(Abe et al., 2010). Intradermal PEDF
administration reduced the thickness
and angiogenesis of grafted epidermis
in xenotransplanted SCID mice (Abe
et al., 2010). We have found PEDF in
psoriatic keratinocytes is elevated,
and PEDF has an inhibitory role in
proliferation and migration of HaCaT
cells, a keratinocyte cell line (Li et al.,
2011). Therefore, the elevation of PEDF
may be an anti-inflammatory system in
patients with psoriasis (Nakajima et al.,
2012).
Inflammatory signal pathways,
including MAPK pathway, Glucocorti-
coid and glucocorticoid receptor (GR),
Sonic Hedgehog (Shh)/Gli pathway, are
involved in the pathogenesis of pso-
riasis. VEGF induces proliferation of
human epidermal keratinocytes and hair
follicle dermal papilla cells through
VEGFR-2-mediated activation of ERK
(Man et al., 2006; Li et al., 2012).
Topical glucocorticoids are the first-
line drugs for inflammatory diseases of
the skin. The efficacy of glucocorticoids
results from the pleiotropic effects of the
GR on multiple signaling pathways
in many target tissues. Keratinocyte-
targeted overexpression of GR delays
cutaneous wound healing and reduces
migration and increases differentiation
of keratinocytes (Sanchis et al., 2012).
Epidermal inactivation of GR triggers
skin barrier defects and cutaneous
inflammation (Sevilla et al., 2013). In
normal skin and cultured human
epidermal keratinocytes, intracellular
GR is localized in the nuclei, while in
psoriatic skin and cultured keratino-
cytes, GR is in the cytoplasm. VEGF
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and IFN-g led to impaired nuclear
translocation of GR through p53 and
microtubule-inhibitor, vincristine, and
inhibited nuclear uptake of GR in
normal keratinocytes. In addition to
dexamethasone, IL-13 was also able to
transfer GR into nuclei of psoriatic
keratinocytes. Furthermore, discontinua-
tion of dexamethasone induced cyto-
plasmic retention of GR in normal
keratinocytes (Man et al., 2013).
Impaired nuclear translocation of GR is
associated with VEGF, IFN-g, p53, and
microtubule. Therapeutic strategies
designed to accumulate GR in the
nucleus, such as IL-13, may be bene-
ficial for the therapy of psoriasis (Man
et al., 2013).
Inhibition of microtubule assembly
also upregulates BMP-2 expression and
enhances Gli2 protein concentrations in
osteoblasts (Zhao et al., 2009). Glis are
the primary transcription factors that
mediate Sonic hedgehog (Shh) signals
in the mouse. Gli1 and Gli2 are mostly
regarded as a transcriptional activator,
while Gli3 mainly acts as a trans-
criptional repressor. Glucocorticoids
can specifically modulate Smo ciliary
accumulation, and there is a potential
crosstalk of glucocorticoids and the
Hedgehog pathway (Wang et al.,
2012). In psoriatic skin, Gli1 is over-
expressed and may decrease neuro-
fibromin expression (Endo et al., 2006).
However, a recent study showed that
absence of elevated Hh target gene
expression in lesional psoriatic skin,
which indicates that the Hh pathway is
not activated in this disease, raising
questions regarding the proposed use
of Hh antagonists as antipsoriatic
agents (Gudjonsson et al., 2009). To
further define the role of Hh signals in
psoriasis, real-time PCR was performed
and showed increased expression of
Shh, Kif7, and Gli1, and decreased
SUFU and Gli3 (Po0.001) of RNA
isolated from epidermis. However,
from whole skin, no difference of Shh,
Kif7, Gli1, and Gli3 was detected, only
decreased SUFU was detected. So, it
seems that further investigation of the
role of Hh signals in psoriasis should be
done.
VEGF-A promotes IL-17 A-producing
gd T-cell accumulation in mouse skin
and serves as a chemotactic factor for
plasmacytoid dendritic cells (Suzuki
et al., 2014). Corticosteroid suppresses
VEGF-A in infantile hemangioma-
derived stem cells (Greenberger et al.,
2010). In addition, overexpression
of PTTG1 in keratinocytes induces
the production of TNF-a, and TNF-a
induces PTTG1 expression (Ishitsuka
et al., 2013). Therefore, there is a link
of angiogenic and inflammatory signals.
In conclusion, the balance between
angiogenic and angiostatic factors has
important roles in psoriasis. Inflamma-
tory signal pathways, glucocorticoids
and their receptor, and MAPK and
Hedgehog/Gli pathways are involved
in the pathogenesis of psoriasis and
therapeutic target for psoriasis. The
angiogenesis and inflammatory path-
ways may form a complex net to control
the onset and maintain psoriasis.
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Figure 1. Effect of an anti-VEGFR-2 antibody (Ab) on psoriatic lesions. (a) The anti-VEGFR-2 antibody reduced the vessels and thickness of the epidermis in SCID-
psoriasis xenograft. (b) The Anti-VEGFR-2 antibody reduced the PASI (**Po0.01) and thickness of epidermis in imiquimod-induced Balb/c psoriasiform skin.
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